[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562468":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":68,"collaborators":10,"id":70,"slug":10,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":10,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Atogepant",null,"Participants will receive atogepant as prescribed by their physician according to the local label.",[13],"Drug: Atogepant",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Oral Tablet",[9],[20,21],"Qulipta","Aquipta",[23],{"name":24,"affiliation":5,"role":25},"ABBVIE INC.","STUDY_DIRECTOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Celine Im","CONTACT","+82-10-2230-3629","celine.im@abbvie.com",[33,46,56,62],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"Hallym University Dongtan Sacred Heart Hospital \u002FID# 273581","RECRUITING","Hwaseong","Gyeonggido","18450","South Korea",{"type":41,"coordinates":42},"Point",[43,44],126.59882,35.24246,{"lat":44,"lon":43},{"facility":47,"status":35,"city":48,"state":49,"zip":50,"country":39,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Seoul National University Hospital \u002FID# 271892","Seoul","Seoul Teugbyeolsi","03080",{"type":41,"coordinates":52},[53,54],126.9784,37.566,{"lat":54,"lon":53},{"facility":57,"status":35,"city":48,"state":49,"zip":58,"country":39,"cosmosGeoPoint":59,"geoPoint":61,"contacts":10},"Kangbuk Samsung Hospital \u002FID# 271893","03181",{"type":41,"coordinates":60},[53,54],{"lat":54,"lon":53},{"facility":63,"status":35,"city":48,"state":49,"zip":64,"country":39,"cosmosGeoPoint":65,"geoPoint":67,"contacts":10},"Yonsei University Health System Severance Hospital \u002FID# 272639","03722",{"type":41,"coordinates":66},[53,54],{"lat":54,"lon":53},{"type":69,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100562468",false,"NCT06603558","Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine","Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients","Atogepant PMSS","Inclusion Criteria:\n\n* Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.\n* Participants prescribed atogepant in accordance with the approved local label.\n\nExclusion Criteria:\n\n* Participants with any contraindication to atogepant as listed on the latest approved local label.\n* Participants currently participating in another clinical research except observational study.","ALL","19 Years",{"count":80,"type":81},3000,"ESTIMATED","OBSERVATIONAL","Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and\u002For sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.\n\nAtogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.\n\nParticipants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.\n\nThere is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.",[85,86,87],"Chronic Migraine","Episodic Migraine","Migraine",[85,86,87,9,20,21],"2026-06-16",{"date":91,"type":92},"2026-06-18","ACTUAL",{"date":94,"type":92},"2024-09-24",{"date":96,"type":81},"2029-05",{"name":5,"class":6},4]